AKT1 and neoplasm: Its activation in certain tumor subpopulations is essential for sustaining malignant behavior and cannot be bypassed by alternative pathways.19,21 While numerous inhibitors targeting key components of the PI3K/AKT pathway have demonstrated initial clinical efficacy, their long-term benefits are often limited by the emergence of drug resistance.